IDRI (Infectious Disease Research Institute) and Medicago Inc. have announced that they will be presenting positive interim Phase I clinical results of their H5N1 Avian Influenza VLP (Virus-Like Particles) vaccine candidate at the upcoming World Vaccine Congress, Washington DC.
In the presentation, titled “H5N1 Phase 1 clinical trial combining Medicago’s VLP vaccine with IDRI’s GLA adjuvant formulation,” Dr Steven Reed, Founder, President and Chief Scientific Officer at the IDRI, and Dr. Brian Ward , Professor of Medicine & Microbiology, McGill University, member of Medicago’s scientific advisory committee, will discuss preliminary safety and immunology data from the ongoing H5N1 vaccine clinical trial.
The H5N1 vaccine candidate includes IDRI’s Glucopyranosyl Lipid A (GLA) adjuvant, and is produced in Medicago’s plant-based expression system, which is speedier than the traditional route of producing flu vaccines in eggs.
“This trial is an important step toward development of an influenza vaccine that could be rapidly and widely administered in case of a pandemic outbreak,” said Dr. Reed, in a press release.
The Phase I clinical trial commenced in September 2012, and enrolled 100 healthy adult volunteers to test for safety and immune response.
Dr Brian Ward has previously spoken at a World Vaccine Congress in 2012. Click here to download his presentation on responding to a rapidly evolving influenza pandemic and Medicago's case study on its plant-derived H5 VLP vaccines.